clinical trial · NCT06219499
Safety, Tolerability, Immunogenicity and Pharmacokinetics of ONC-841
OncoC4, Inc.·phase1·withdrawn
Advanced Solid TumorONC-841Placebo
brief summary
The Phase 1 study is a randomized, double-blind, placebo-controlled, single ascending dose, multi-cohort study. The study will evaluate 5 dose levels of the investigational product, in 5 cohorts of 8 healthy volunteers per cohort. In each cohort, 6 volunteers will receive the investigational product and 2 volunteers will receive placebo.
started
Jun 1, 2024
primary completion
Jun 1, 2025
completion
Jun 1, 2026
last updated
Apr 3, 2024
official title
A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Immunogenicity and Pharmacokinetics of ONC-841 When Administered Intravenously in Healthy Adult Subjects
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol